Indaptus Therapeutics is trading 8.5% up now at $1.15 after its August 13, 2026, second-quarter results reportedly beat estimates, with a narrowed $1.8 million net loss and EPS of $(0.02).
- Cash and short-term investments totaled $11.6 million.
- The company discontinued Decoy20 enrollment and is evaluating strategic alternatives, including neurological research collaborations.
- The earnings release appears to be the clearest catalyst, despite uncertainty from halted clinical development.